Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that all 84 U.S. sites for its pivotal Phase 3 trial in early Alzheimer’s disease are now fully activated and enrolling, with most already treating patients. The first group of participants has completed the 6-month treatment phase, keeping the company on schedule to deliver symptomatic data in the second half of 2026. CEO Maria Maccecchini said the study, now 25% complete, reflects strong execution and continued momentum toward bringing buntanetap to patients in need of effective therapies.
This milestone is significant because it demonstrates Annovis Bio’s ability to rapidly enroll and treat patients in a large-scale pivotal trial, a critical step toward potential regulatory approval. The completion of the first patient cohort’s treatment phase provides early safety and efficacy signals that will inform the final data readout. The company’s focus on early Alzheimer’s disease addresses a high unmet medical need, as current treatments offer limited benefit in halting disease progression. Annovis’s drug candidate, buntanetap, targets multiple pathways implicated in neurodegeneration, potentially offering a more comprehensive therapeutic approach.
Investors will be watching for the symptomatic data in 2026, which could be a catalyst for the stock if positive. The successful activation of all sites and patient completions reduce execution risk and bolster confidence in the trial’s timeline. Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. For more information, visit www.annovisbio.com.
The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
